Lonza enters worldwide exclusive licensing and supply accord with California Stem Cell

The US subsidiary of Switzerland's Lonza has entered a worldwide, exclusive licensing and supply agreements with California Stem Cell. The Lonza/California Stem Cell collaboration makes novel pluripotent stem cell products readily available to researchers worldwide.

The US firm's proprietary methods for scalable production of multiple cell types from human pluripotent stem cells (hPSC), combined with Lonza's extensive primary cell expertise, specifically enhance screening tools and improve the predictive strength of current cell based models.

'This partnership will address the evolving needs of the research community by making broadly available high purity, human pluripotent stem cell-derived cells and related media products, worldwide,' said Hans Keirstead, chairman of California Stem Cell's scientific advisory board. 'California Stem Cell's ability to create innovative tools derived from pluripotent stem cells, combined with Lonza's world-class manufacturing and marketing capabilities, will provide valuable products to accelerate drug discovery and other translational research and development,' he added.